Literature DB >> 21807800

Valuing health for clinical and economic decisions: directions relevant for rheumatologists.

Mark J Harrison1, Nick J Bansback, Carlo A Marra, Michael Drummond, Peter S Tugwell, Annelies Boonen.   

Abstract

The quality-adjusted life-year (QALY) is a construct that integrates the value or preference for a health state over the period of time in that health state. The main use of QALY is in cost-utility analysis, to help make resource allocation decisions when faced with choices. Although the concept of the QALY is appealing, there is ongoing debate regarding their usefulness and approaches to deriving QALY. In 2008, OMERACT engaged in an effort to agree on QALY approaches that can be used in rheumatology. Based on a Web questionnaire and a subsequent meeting, rheumatologists questioned whether it was relevant for OMERACT (1) to investigate use of a QALY that represents the patients' perspective, (2) to explore the validity of the visual analog scale (VAS) to value health, and (3) to understand the validity of mapping health-specific instruments on existing preference instruments. This article discusses the pros and cons of these points in light of current insight from the point of view of health economics and decision-making theory. It also considers the further research agenda toward a QALY approach in rheumatology.

Entities:  

Mesh:

Year:  2011        PMID: 21807800     DOI: 10.3899/jrheum.110404

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.

Authors:  Zsombor Zrubka; Fanni Rencz; Jakub Závada; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Valentin Brodszky; Petra Baji; Guenka Petrova; Alexandru Rotar; László Gulácsi; Márta Péntek
Journal:  Rheumatol Int       Date:  2017-08-28       Impact factor: 2.631

2.  Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials.

Authors:  Michael M Ward; Lori C Guthrie
Journal:  Rheumatology (Oxford)       Date:  2016-10-27       Impact factor: 7.580

Review 3.  Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review.

Authors:  Jonathan Tosh; Matt Stevenson; Ron Akehurst
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

4.  Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.

Authors:  Dennis W Raisch; Patricia Feeney; David C Goff; K M Venkat Narayan; Patrick J O'Connor; Ping Zhang; Don G Hire; Mark D Sullivan
Journal:  Cardiovasc Diabetol       Date:  2012-07-11       Impact factor: 9.951

5.  EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Authors:  Anders Gülfe; Johan K Wallman; Lars Erik Kristensen
Journal:  Arthritis Res Ther       Date:  2016-02-19       Impact factor: 5.156

6.  The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.

Authors:  Mónica Hernández Alava; Allan Wailoo; Fred Wolfe; Kaleb Michaud
Journal:  Rheumatology (Oxford)       Date:  2013-01-21       Impact factor: 7.580

7.  Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation.

Authors:  M Hiligsmann; J-Y Reginster; A N A Tosteson; S V Bukata; K G Saag; D T Gold; P Halbout; F Jiwa; E M Lewiecki; D Pinto; J D Adachi; N Al-Daghri; O Bruyère; M Chandran; C Cooper; N C Harvey; T A Einhorn; J A Kanis; D L Kendler; O D Messina; R Rizzoli; L Si; S Silverman
Journal:  Osteoporos Int       Date:  2018-10-31       Impact factor: 4.507

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.